| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/15/2009 | WO2008074867A3 Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use |
| 01/15/2009 | WO2008067547A3 Improved immunoglobulin libraries |
| 01/15/2009 | WO2008021408A3 Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy |
| 01/15/2009 | WO2007092419A3 Method for non-invasive detection and treatment of cerebral aneurysms |
| 01/15/2009 | US20090018316 Propagating interleukin-15 specific monoclonal antibody for use as tool in controllig immune response |
| 01/15/2009 | US20090018315 B7-H3 and B7-H4, Novel Immunoregulatory Molecules |
| 01/15/2009 | US20090018314 low affinity receptor for IgE (FceRII/CD23); for modulating or inhibiting induced IgE expression; allergic conditions, autoimmune and inflammatory diseases |
| 01/15/2009 | US20090018086 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus |
| 01/15/2009 | US20090018081 Activatable clostridial toxins |
| 01/15/2009 | US20090018077 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018076 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018071 Epididymis-specific receptor protein |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090018066 Pharmaceutical compositions for modulating the activity of a novel triglyceride hydrolase |
| 01/15/2009 | US20090018030 Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications |
| 01/15/2009 | US20090017559 Methods for diagnosing renal disorders |
| 01/15/2009 | US20090017557 FVII Specific Antibodies and Use Thereof |
| 01/15/2009 | US20090017556 Methods and complexes involving immunoglobulin molecule |
| 01/15/2009 | US20090017538 For modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein |
| 01/15/2009 | US20090017534 Nucleotide sequences coding voltage-gated transport proteins for use as screening tools to identify modulators for treatment and prevention of nervous, muscular, glandular, immune, reproductive and epithelial tissue disorders |
| 01/15/2009 | US20090017532 Vector |
| 01/15/2009 | US20090017522 proteolytic fragment of a growth differentiation factor (GDF) polypeptide (pro-GDF) or a functional peptide portion thereof; affects activity associated with GDF signal transduction |
| 01/15/2009 | US20090017494 Tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/15/2009 | US20090017492 SVPH1-26 DNA and polypeptides |
| 01/15/2009 | US20090017479 Ly6h gene |
| 01/15/2009 | US20090017473 Compositions and methods for the diagnosis and treatment of tumor |
| 01/15/2009 | US20090017467 COMPOSITION EXHIBITING A VON WILLEBRAND FACTOR (vWF) PROTEASE ACTIVITY COMPRISING A POLYPEPTIDE CHAIN WITH THE AMINO ACID SEQUENCE AAGGILHLELLV |
| 01/15/2009 | US20090017046 Using lymphocyte antigen binding profiles to diagnose and treat cancer; antitumor agents; administering an antibody or antigen binding fragment thereof that specifically binds to upregulated OX-2/CD200 |
| 01/15/2009 | US20090017044 Antibodies to the Human Prolactin Receptor |
| 01/15/2009 | US20090017043 Connective tissues growth factor antibodies |
| 01/15/2009 | US20090017041 Monoclonal antibody |
| 01/15/2009 | US20090017040 Monoclonal antibody |
| 01/15/2009 | US20090017039 SP35 Antibodies and uses thereof |
| 01/15/2009 | US20090017038 Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods |
| 01/15/2009 | US20090017037 Human TIMP-1 Antibodies |
| 01/15/2009 | US20090017035 Human antibodies to human delta like ligand 4 |
| 01/15/2009 | US20090017034 inhibits thymic stromal lymphopoietin TSLP)-mediated lymphocyte stimulation; using these polypeptides as molecular weight markers that allow the estimation of the molecular weight of a protein or a fragmented protein |
| 01/15/2009 | US20090017033 Inhibiting receptor activated nuclear factor kappa beta ligand (RANKL); immunoregulation |
| 01/15/2009 | US20090017032 Mammalian cx3c chemokine antibodies |
| 01/15/2009 | US20090017031 Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| 01/15/2009 | US20090017030 Endothelial Cell Expression Patterns |
| 01/15/2009 | US20090017028 Antigen binding fragments (fab fragments) binds to a plurality of beta-chemokines; glomerulonephritis, scleroderrna, cirrhosis, multiple sclerosis, lupus nephritis, atherosclerosis, inflammatory bowel disease or rheumatoid arthritis; antiinflammatory agents |
| 01/15/2009 | US20090017027 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017026 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017023 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 01/15/2009 | US20090017020 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| 01/15/2009 | US20090017018 Uses of mammalian cytokine: related reagents |
| 01/15/2009 | US20090017017 Anti-rhesus d recombinant polyclonal antibody and methods of manufacture |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | US20090017011 Modulation of vegf-c/vegfr-3 interactions in the treatment of rheumatoid arthritis |
| 01/15/2009 | US20090016989 Antibodies to human somatostatin receptor and methods of use |
| 01/15/2009 | US20090016988 Modified Pore-Forming Protein Toxins and Use Thereof |
| 01/15/2009 | US20090016965 Internal image antibodies for optical imaging and therapy |
| 01/15/2009 | US20090016959 Drug delivery across the blood-brain barrier using polypeptides; neurological diseases; aprotinin |
| 01/15/2009 | US20090014562 Spray Nozzle Apparatus and Method of Use |
| 01/15/2009 | CA2696145A1 Method for removing endotoxin from proteins |
| 01/15/2009 | CA2694721A1 Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| 01/15/2009 | CA2694418A1 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 01/15/2009 | CA2693651A1 Bioactive peptides and method of using same |
| 01/15/2009 | CA2693611A1 Novel formulation |
| 01/15/2009 | CA2693455A1 An antibody specific for the tn antigen for the treatment of cancer |
| 01/15/2009 | CA2692453A1 Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut8) gene expression |
| 01/15/2009 | CA2680741A1 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 01/14/2009 | EP2014770A2 WNT-1 Iinduced secreted polypeptide WISP-2 |
| 01/14/2009 | EP2014681A1 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 01/14/2009 | EP2014680A1 Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014675A1 Compositions and methods for the treatment of immune related diseases |
| 01/14/2009 | EP2014673A1 Tumour-associated peptides which bind to MHC molecules |
| 01/14/2009 | EP2014302A1 An antibody specific for the Tn antigen for the treatment of cancer |
| 01/14/2009 | EP2014301A1 Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
| 01/14/2009 | EP2014298A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014180A1 Composition useful for the reduction of the cardivascular risk and foods that contain it |
| 01/14/2009 | EP2013625A2 Use of the chain of brain spectrin and fragments thereof, for diagnosing cerebral diseases |
| 01/14/2009 | EP2013621A1 ANTI-FACTOR XIIa THERAPY |
| 01/14/2009 | EP2013337A2 A group of esterases for the enantioselective production of fine and speciality chemicals |
| 01/14/2009 | EP2013236A1 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
| 01/14/2009 | EP2013235A1 Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| 01/14/2009 | EP2013226A2 Processes for the preparation of octreotide |
| 01/14/2009 | EP2012825A2 Methods and compositions for preventing and treating streptococcus pneumoniae infection |
| 01/14/2009 | EP2012824A2 Uses and compositions for treatment of psoriasis |
| 01/14/2009 | EP2012814A1 Methods of treating autoimmune diseases |
| 01/14/2009 | EP1869462A4 Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| 01/14/2009 | EP1659918B1 Antibodies directed to parathyroid hormone (pth) and uses thereof |
| 01/14/2009 | EP1653844A4 Prion-specific peptide reagents |
| 01/14/2009 | EP1609858B1 Method for detecting substrates or inhibitors for branched neutral amino acid transporters |
| 01/14/2009 | EP1572967B1 Il-1 receptor based antagonists and methods of making and using |
| 01/14/2009 | EP1549741B1 Novel endothelial cells, antibodies against said cells and use thereof |
| 01/14/2009 | EP1485412B1 Repressor of skeletal muscle differentiation, nucleic acids coding therefor and the use thereof in diagnosis and therapy |
| 01/14/2009 | EP1456386B1 Polycistronic expression of antibodies in cho cells |
| 01/14/2009 | EP1423133B1 Treatment of muscular dystrophies and related disorders |
| 01/14/2009 | EP1390389B1 Cripto blocking antibodies and uses thereof |
| 01/14/2009 | EP1377305B1 Tryptophanyl-trna synthetase derived polypeptides useful for the regulation of an-giogenesis |
| 01/14/2009 | EP1360314B1 Chemically defined medium for cultured mammalian cells |
| 01/14/2009 | EP1341810B1 Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type iii secretion pathway of a gram-negative bacteria. |
| 01/14/2009 | EP1297142B1 Dual specificity antibodies and methods of making and using |
| 01/14/2009 | EP1283057B1 Cell proliferation inhibitors |
| 01/14/2009 | EP1187918B2 Tek antagonists |
| 01/14/2009 | EP1183049B1 Modification of biological elements |